News

The 5 Most Interesting Analyst Questions From Guardant Health’s Q2 Earnings Call

Guardant Health’s second quarter results reflected robust demand across its core oncology and screening businesses, yet the ...

GH Q2 Deep Dive: Strong Volume Growth and Product Expansion Amid Profitability Challenges

Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q2 CY2025, with sales up 30.9% year ...

TD Cowen Reaffirms Their Buy Rating on Guardant Health (GH)

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.